Clinical Trial Update: Biomarker Testing and DNA Collection in Subjects Participating in Protocol 22001

View source ↗

Summary

This clinical trial update documents biomarker testing and DNA collection procedures for subjects enrolled in Protocol 22001 for Fragile X Syndrome.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fragile Syndrome

Snippet

Sponsor: Seaside Therapeutics, Inc. | Conditions: Fragile X Syndrome | Status: COMPLETED